Allworth Financial LP Has $1.11 Million Holdings in AstraZeneca PLC $AZN

Allworth Financial LP grew its stake in AstraZeneca PLC (NASDAQ:AZN) by 25.9% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,850 shares of the company’s stock after purchasing an additional 3,264 shares during the period. Allworth Financial LP’s holdings in AstraZeneca were worth $1,108,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. SCS Capital Management LLC bought a new position in AstraZeneca in the first quarter worth $3,066,000. Robbins Farley bought a new position in shares of AstraZeneca during the 2nd quarter worth about $1,857,000. Oliver Luxxe Assets LLC lifted its holdings in shares of AstraZeneca by 6.0% during the 2nd quarter. Oliver Luxxe Assets LLC now owns 78,301 shares of the company’s stock worth $5,472,000 after acquiring an additional 4,449 shares during the period. Jennison Associates LLC boosted its position in shares of AstraZeneca by 15.2% during the 2nd quarter. Jennison Associates LLC now owns 12,167,365 shares of the company’s stock valued at $850,255,000 after acquiring an additional 1,605,133 shares in the last quarter. Finally, Alhambra Investment Management LLC bought a new stake in AstraZeneca in the second quarter valued at about $320,000. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Price Performance

AstraZeneca stock opened at $89.10 on Friday. The business’s fifty day moving average is $82.13 and its two-hundred day moving average is $76.17. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.67 and a current ratio of 0.86. The firm has a market cap of $276.34 billion, a P/E ratio of 33.50, a P/E/G ratio of 1.52 and a beta of 0.34. AstraZeneca PLC has a 52 week low of $61.24 and a 52 week high of $89.43.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings results on Thursday, November 6th. The company reported $1.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.14 by $0.05. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.The business had revenue of $15.19 billion during the quarter, compared to analysts’ expectations of $14.75 billion. During the same period in the previous year, the business posted $2.08 earnings per share. The firm’s revenue for the quarter was up 12.0% compared to the same quarter last year. Equities research analysts forecast that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on AZN. Weiss Ratings restated a “buy (b)” rating on shares of AstraZeneca in a research note on Wednesday, October 8th. Deutsche Bank Aktiengesellschaft downgraded AstraZeneca from a “hold” rating to a “sell” rating in a research report on Thursday, October 16th. Finally, Jefferies Financial Group initiated coverage on AstraZeneca in a research report on Monday, October 27th. They issued a “buy” rating on the stock. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $86.00.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.